<DOC>
	<DOCNO>NCT02538354</DOCNO>
	<brief_summary>This study evaluate suppelementation diet riboflavin Crohn 's disease patient result increase amount F. prausnitzii .</brief_summary>
	<brief_title>The Effect Riboflavin Crohn 's Disease</brief_title>
	<detailed_description>Rationale Recent study show patient Inflammatory Bowel Disease ( IBD ) dysbiosis exist composition intestinal microbiota . In particular , potentially pathogenic bacterium Escherichia coli ( E. coli ) often abundant bowel IBD patient , anaerobic commensal Faecalibacterium prausnitzii ( F. prausnitzii ) often reduce . This last mentioned bacteria know abundant intestine healthy individual . It known produce butyrate , stimulate intestinal epithelium , secrete anti-inflammatory substance . Riboflavin - also know vitamin B2 - require wide variety cellular process important role maintain health human . In pilot intervention healthy volunteer show riboflavin supplement increase number F. prausnitzii result high production butyrate . In Crohn 's disease patient , know amount F. prausnitzii intestine generally low . Furthermore , know association number F. prausnitzii bacteria length disease remission . This study evaluate supplementation diet riboflavin Crohn 's disease patient result similar increase amount F. prausnitzii healthy volunteer . In patient group , increase number F. prausnitzii bacteria bowel may result favourable disease course . This assessed faeces calprotectin two questionnaire . Additionally investigator assess modulation riboflavin intestinal bacteria , short chain fatty acid ( SCFAs ) ( butyrate ) , pH faeces . Finally , effect riboflavin permeability gut evaluate Chroom-EDTA test , number different biomarkers permeability . Hypothesis The hypothesis Crohn 's disease patient , supplementation diet riboflavin result increase amount F. prausnitzii , change microbial composition , increase fatty acid production , increase pH reduction intestinal permeability . These change might result favourable disease course less exacerbation . Study design Prospective clinical study . Study population sample size In total 84 Crohn 's disease patient include study , divide two group . Group 1 ( n=42 ) consist patient disease remission ( quiescent disease ) ; group 2 ( n=42 ) consist patient active disease . In study adaptive design use . First 12 patient disease remission group analyse . The method analysis safety aspects take account . Intervention Supplementation normal diet 1 capsule 100 mg riboflavin ( vitamin B2 ) three week .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Crohn 's disease patient Age 1865 year Concomitant medication Crohn 's disease allow group Swallowing disorder Pregnancy lactation Use antibiotic drug , probiotic ( i.e.Yakult , Vifit , Activia etc ) specific prebiotic supplement 3 week prior riboflavin intervention Use Methotrexate drug Colonoscopy colon cleanse last 3 month Use vitamin B2 supplement , multivitamin complex contain vitamin B ( i.e . vitamin Bcomplex ) 3 week prior riboflavin intervention Severe Crohn 's disease ( HBI &gt; 12 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Riboflavin ( vitamin B2 )</keyword>
	<keyword>Faecalibacterium prausnitzii</keyword>
</DOC>